Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Allon Therapeutics, a British Columbia-based clinical-stage biotechnology company that develops first drugs to combat the progression of neurodegenerative diseases, has been granted a patent by the Japan Patent Office which covers the composition of Allon’s lead product davunetide.
Subscribe to our email newsletter
The patent also covers the polypeptide and nucleotide composition of matter for davunetide, its parent protein activity-dependent neuroprotective protein (ADNP) and other derivatives of ADNP.
Currently, davunetide is being evaluated in a Phase 2/3 clinical trial as a potential treatment for progressive supranuclear palsy (PSP), a rapidly progressing and fatal degenerative brain disease often misdiagnosed as Parkinson’s or Alzheimer’s disease.
Allon Therapeutics vice president of Commercial Research Alistair Stewart said the Japanese patent expands the davunetide’s commercial market potential beyond North America and Europe.
"Davunetide’s clinical development has reached the stage where its commercialization is on the horizon, and the patent portfolio becomes critical to efforts in attracting pharma companies which are potential commercialization partners," said Stewart.
Allon Therapeutics has been granted another patent in the US for davunetide use to treat fetal alcohol syndrome.